sb 202190 has been researched along with Respiratory Distress Syndrome in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, Y | 1 |
| Kim, HP | 1 |
| Chi, M | 1 |
| Ifedigbo, E | 1 |
| Ryter, SW | 1 |
| Choi, AM | 1 |
1 other study available for sb 202190 and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Deletion of caveolin-1 protects against oxidative lung injury via up-regulation of heme oxygenase-1.
Topics: Animals; Bronchoalveolar Lavage Fluid; Caveolin 1; Cell Death; Endothelial Cells; Epithelial Cells; | 2008 |